체외 혈액 치료 시장 규모 : 치료 유형별, 용도별, 최종 사용자별, 지역별 예측

Extracorporeal Blood Treatment Market Size and Forecast

Market capitalization in the extracorporeal blood treatment market reached a significant USD 5.04 Billion in 2025 and is projected to maintain a strong 7.2% CAGR during the forecast period from 2027 to 2033. A company-wide policy adopting advanced touch panel technologies and interactive display solutions for consumer electronics runs as the strong main factor for great growth. The market is projected to reach a figure of USD 8.81 Billion by 2033, indicating a significant reassessment of the entire economic landscape.

Global Extracorporeal Blood Treatment Market Overview

Extracorporeal blood treatment refers to a category of medical therapies in which blood is removed from the body, processed through an external device to remove toxins, excess fluids, or harmful substances, and then returned to the patient's circulation. The term defines treatment systems that combine filtration, or dialysis technologies to support patients with severe medical conditions such as kidney failure, sepsis, liver dysfunction, and certain autoimmune disorders. The scope typically includes devices and treatment procedures such as hemodialysis, plasmapheresis, and hemoperfusion used in hospitals, dialysis centers, and critical care units.

In market research, extracorporeal blood treatment solutions are treated as a standardized segment within advanced medical treatment and critical care technologies to maintain consistency in demand analysis, clinical adoption tracking, and technology benchmarking. The market includes treatment equipment, filtration cartridges, and supporting monitoring systems that enable safe and effective blood purification outside the body. Adoption is closely linked to hospital infrastructure, clinical protocols, and the availability of specialized medical staff capable of managing extracorporeal treatment procedures.

Key factors influencing purchasing decisions include treatment efficiency, patient safety, device reliability, and compatibility with existing clinical systems rather than simple equipment volume growth. Pricing trends generally reflect technology sophistication, disposable component usage, and healthcare reimbursement structures. Short- to medium-term market activity aligns with rising incidence of chronic kidney disease, increasing demand for critical care treatments, and continued expansion of advanced blood purification technologies used in intensive care and specialized treatment centers.

Global Extracorporeal Blood Treatment Market Drivers

The market drivers for the extracorporeal blood treatment market can be influenced by various factors. These may include:

Prevalence of Chronic Kidney Diseases and Cardiovascular Disorders: The increasing incidence of chronic kidney disease (CKD), end-stage renal disease (ESRD), and cardiovascular disorders is driving demand for extracorporeal blood treatment (EBT) therapies. Hemodialysis, hemofiltration, and apheresis procedures are commonly used to manage these conditions, offering life-saving support and improving patient outcomes. Studies indicate that CKD affects over 10% of the global adult population, with rising cases in aging populations. The growing patient pool requiring dialysis and related blood treatment therapies is a primary driver of the EBT market.

Technological Advancements in Blood Treatment Devices: Innovations in extracorporeal blood treatment systems, including portable dialysis machines, continuous renal replacement therapy (CRRT) devices, and biocompatible filters, are enhancing treatment efficiency and patient safety. Research shows that advanced hemodialysis technologies can improve treatment outcomes by 15-20% compared to conventional systems. Continuous technological improvements are expanding the adoption of EBT systems in hospitals and specialized clinics.

Increasing Demand for Home-Based and Outpatient Treatments: There is a growing preference for home dialysis and outpatient extracorporeal blood treatments due to convenience, cost savings, and reduced hospital visits. Portable and user-friendly EBT systems allow patients to manage their therapy in home settings under remote monitoring. Studies indicate that home hemodialysis can reduce healthcare costs by 20-30% while improving patient quality of life. This trend is supporting market growth, particularly in developed regions with aging populations and well-established healthcare infrastructure.

Supportive Government Policies and Reimbursement Programs: Government initiatives, healthcare insurance coverage, and reimbursement schemes for dialysis and blood treatment procedures are encouraging wider adoption of EBT systems. Many countries provide funding and subsidies for dialysis patients, making treatment more accessible. Reports show that reimbursement policies significantly impact patient uptake and healthcare facility investments in extracorporeal blood treatment devices.

Global Extracorporeal Blood Treatment Market Restraints

Several factors act as restraints or challenges for the extracorporeal blood treatment market. These may include:

High Equipment and Operational Costs: High equipment and operational costs are restraining the growth of the extracorporeal blood treatment market. Devices used for procedures such as hemodialysis, plasmapheresis, and hemofiltration require advanced technology, durable components, and specialized consumables. In addition to initial purchase costs, ongoing expenses include maintenance, replacement parts, and sterilization processes. These financial demands can limit adoption, especially in smaller healthcare facilities or regions with constrained healthcare budgets.

Complex Clinical Procedures and Skilled Workforce Requirements: The complexity of extracorporeal blood treatment procedures limits market expansion. Treatments require trained medical professionals, including nurses and technicians, to operate equipment and monitor patients during therapy. Staffing shortages or inadequate training can hinder effective utilization and slow adoption. The need for highly skilled personnel increases operational costs and may restrict deployment in under-resourced healthcare settings.

Regulatory and Compliance Challenges: Strict regulatory and compliance requirements act as a restraint in the market. Extracorporeal treatment devices and procedures are subject to medical device approvals, clinical safety standards, and healthcare regulations. Navigating these regulatory frameworks involves extensive documentation, testing, and quality assurance processes. Compliance adds to the cost and time of market entry, particularly in regions with rigorous healthcare regulations.

Risk of Complications and Patient Safety Concerns: The risk of complications and patient safety concerns limits the widespread adoption of extracorporeal blood treatments. Procedures such as hemodialysis or plasmapheresis carry risks including infection, bleeding, or hemodynamic instability. Healthcare providers must implement strict monitoring protocols and safety measures, which increases operational complexity. Concerns over adverse events can also influence patient willingness to undergo treatment and affect hospital adoption rates.

Global Extracorporeal Blood Treatment Market Segmentation Analysis

The Global Extracorporeal Blood Treatment Market is segmented based on Treatment Type, Application, End-User, and Geography.

Extracorporeal Blood Treatment Market, By Treatment Type

In the extracorporeal blood treatment market, dialysis dominates the extracorporeal blood treatment market as the primary therapy for chronic kidney disease and acute renal failure, using hemodialysis and peritoneal systems to remove toxins and excess fluids. Plasmapheresis is growing steadily neurological disorders by removing and replacing plasma to eliminate harmful antibodies. Hospitals and specialty clinics are increasingly adopting both therapies to address rising demand for renal and blood-related treatments. The market dynamics for each treatment type are broken down as follows:

Dialysis: Dialysis represents the largest segment in the extracorporeal blood treatment market, as it is the standard therapy for patients with chronic kidney disease (CKD) and acute renal failure. Hemodialysis and peritoneal dialysis systems are widely used to remove toxins, excess fluids, and waste products from the blood when the kidneys cannot perform these functions effectively. Growth in this segment is driven by the rising prevalence of kidney-related disorders, and increasing awareness of renal care.

Plasmapheresis: Plasmapheresis is experiencing steady growth as a treatment for autoimmune diseases, neurological disorders, and certain blood-related conditions. The procedure involves removing plasma from the patient's blood and replacing it with donor plasma or a plasma substitute to eliminate harmful antibodies or toxins. Hospitals, specialty clinics, and blood centers are increasingly adopting plasmapheresis due to its effectiveness in treating conditions such as myasthenia gravis, Guillain-Barre syndrome, and hyperviscosity syndrome.

Extracorporeal Blood Treatment Market, By Application

In the extracorporeal blood treatment market, renal disorders lead the extracorporeal blood treatment market, with dialysis serving as the main therapy for CKD, acute kidney injury, and ESRD patients. Growth is driven by rising kidney disease prevalence, aging populations, and greater awareness of early treatment. Cardiovascular disorders also utilize extracorporeal treatments, including cardiopulmonary bypass and lipid apheresis. Increasing cardiovascular disease incidence and advancements in device safety and efficiency are supporting growth in this segment. The market dynamics for each application are broken down as follows:

Renal Disorders: Renal disorders account for the largest share of the extracorporeal blood treatment market, with dialysis being the primary treatment modality. Patients with chronic kidney disease (CKD), acute kidney injury, or end-stage renal disease (ESRD) rely on hemodialysis or peritoneal dialysis to manage waste removal and fluid balance. Market growth is driven by the rising prevalence of kidney-related conditions, aging populations, and increased awareness about early diagnosis and treatment.

Cardiovascular Disorders: Extracorporeal blood treatments are also used in managing cardiovascular disorders, including cardiopulmonary bypass procedures, apheresis for lipid management, and treatment of certain blood clotting disorders. Increasing incidence of cardiovascular diseases, coupled with improvements in device safety, efficiency, and automation, is driving steady growth in this application segment.

Extracorporeal Blood Treatment Market, By End-User

In the extracorporeal blood treatment market, hospitals are the largest end-users of extracorporeal blood treatment, offering comprehensive care through advanced renal and critical care units. Dialysis centers focus on routine hemodialysis and peritoneal dialysis for CKD and ESRD patients, benefiting from specialized care and cost-effective treatment models. Ambulatory surgical centers are adopting these treatments for outpatient procedures, providing convenient, lower-cost alternatives to hospitals. Growth across all segments is driven by rising chronic kidney and cardiovascular cases, expanding infrastructure, and increased adoption of advanced blood treatment technologies. The market dynamics for each end-user are broken down as follows:

Hospitals: Hospitals represent the largest end-user segment for extracorporeal blood treatment, providing comprehensive care for patients requiring dialysis, plasmapheresis, and cardiopulmonary support. Large hospital networks often have dedicated renal and critical care units equipped with advanced extracorporeal treatment systems. Growth in this segment is driven by the increasing number of chronic kidney and cardiovascular patients, expanding hospital infrastructure, and rising adoption of technologically advanced blood treatment devices.

Dialysis Centers: Dialysis centers form a key end-user segment, catering specifically to patients with chronic kidney disease and end-stage renal disease. These centers focus on providing routine hemodialysis and peritoneal dialysis services, often with multiple sessions per week. Expansion of standalone and chain dialysis centers, along with rising awareness of home dialysis options, is driving steady growth. The segment benefits from specialized care models and cost-effective treatment delivery outside traditional hospital settings.

Ambulatory Surgical Centers: Ambulatory surgical centers are increasingly adopting extracorporeal blood treatment solutions for outpatient procedures that require temporary blood filtration or plasma exchange. ASCs offer a convenient, lower-cost alternative to hospitals for certain treatments, supporting efficiency and patient comfort. Growth in this segment is supported by the rise of minimally invasive procedures, outpatient cardiovascular interventions, and specialized plasma exchange therapies. The trend toward outpatient care and shorter hospital stays is expected to drive moderate growth for this end-user segment.

Extracorporeal Blood Treatment Market, By Geography

In the extracorporeal blood treatment market, North America leads the extracorporeal blood treatment market with widespread dialysis and ECMO adoption. Europe shows steady growth through expanding dialysis and plasma exchange services. Asia Pacific is rapidly growing due to rising chronic disease prevalence and improved healthcare facilities. Latin America and the Middle East & Africa are emerging markets, increasingly investing in advanced blood treatment and healthcare infrastructure. The market dynamics for each region are broken down as follows:

North America: North America is a leading market for extracorporeal blood treatment, driven by the high prevalence of chronic kidney disease, cardiovascular disorders, and increasing demand for advanced dialysis and apheresis procedures in the United States and Canada. Cities such as New York, Los Angeles, and Toronto are witnessing growing adoption of hemodialysis, hemofiltration, and extracorporeal membrane oxygenation (ECMO) technologies.

Europe: Europe is witnessing steady growth in the extracorporeal blood treatment market, with countries including Germany, France, and the United Kingdom showing strong adoption. Cities like Berlin, Paris, and London are expanding clinical use of dialysis centers, plasma exchange, and ECMO procedures to treat patients with renal and cardiovascular conditions. Increasing healthcare expenditure and government support for advanced treatment technologies are driving regional market expansion.

Asia Pacific: Asia Pacific is on a strong growth trajectory, led by countries such as China, India, Japan, and South Korea. Urban centers including Shanghai, Tokyo, Mumbai, and Seoul are experiencing rising demand for extracorporeal blood treatment due to growing chronic disease prevalence, improving hospital infrastructure, and rising patient awareness. Increasing investments in healthcare services and expansion of specialty treatment centers are fueling regional market growth.

Latin America: Latin America is gradually expanding its extracorporeal blood treatment market, particularly in Brazil, Mexico, and Argentina. Cities such as Sao Paulo, Mexico City, and Buenos Aires are witnessing growing adoption of dialysis, apheresis, and ECMO treatments. Rising prevalence of renal disorders and increasing healthcare facility modernization are driving market development in the region.

Middle East and Africa: The Middle East and Africa are emerging markets for extracorporeal blood treatment, with countries such as the United Arab Emirates, Saudi Arabia, and South Africa showing increasing adoption. Cities including Dubai, Riyadh, and Johannesburg are seeing growth in advanced dialysis and blood purification procedures. Expanding healthcare infrastructure, government initiatives to improve chronic disease management, and rising awareness of treatment options are supporting market growth across the region.

Key Players

• The competitive landscape is increasingly determined by how well players adjust to new consumer values, even though it is still based on brand equity and scale. Even though market consolidation continues to change the strategic map, supply chain ethics, scientific innovation in comfort, and verifiable eco-credentials are now the main areas of strategic differentiation.
• Key Players Operating in the Global Extracorporeal Blood Treatment Market
• PPG
• BASF
• Sherwin-Williams
• Mankiewicz
• AkzoNobel
• Henkel
• Hentzen
• MAPAERO
• Permagard
• Dunmore
• Hexion

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA END-USERS

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET OVERVIEW
• 3.2 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY TREATMENT TYPE
• 3.8 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.9 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY END-USER
• 3.10 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.11 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET, BY TREATMENT TYPE(USD BILLION)
• 3.12 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET, BY APPLICATION (USD BILLION)
• 3.13 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET, BY END-USER(USD BILLION)
• 3.14 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET, BY GEOGRAPHY (USD BILLION)
• 3.15 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET EVOLUTION
• 4.2 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKETRESTRAINTS
• 4.5 MARKETTRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE APPLICATION
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY TREATMENT TYPE

• 5.1 OVERVIEW
• 5.2 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TREATMENT TYPE
• 5.4 DIALYSIS
• 5.5 PLASMAPHERESIS

6 MARKET, BY APPLICATION

• 6.1 OVERVIEW
• 6.2 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
• 6.3 RENAL DISORDERS
• 6.4 CARDIOVASCULAR DISORDERS

7 MARKET, BY END-USER

• 7.1 OVERVIEW
• 7.2 GLOBAL EXTRACORPOREAL BLOOD TREATMENT MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END-USER
• 7.3 HOSPITALS
• 7.4 DIALYSIS CENTERS
• 7.5 AMBULATORY SURGICAL CENTERS

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 ARGENTINA
  • 8.5.3 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 UAE
  • 8.6.2 SAUDI ARABIA
  • 8.6.3 SOUTH AFRICA
  • 8.6.4 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 MAPA PROFESSIONAL
• 9.3 SUPERMAX CORPORATION BERHAD
• 9.4 KOSSAN RUBBER INDUSTRIES
  • 9.4.1 SHOWA GROUP
  • 9.4.2 MERCATOR MEDICAL
  • 9.4.3 HARTALEGA HOLDINGS
  • 9.4.4 RUBBEREX

10 COMPANY PROFILES

• 10.1 OVERVIEW
• 10.2 PPG
• 10.3 BASF
• 10.4 SHERWIN-WILLIAMS
• 10.5 MANKIEWICZ
• 10.6 AKZONOBEL
• 10.7 HENKEL
• 10.8 HENTZEN
• 10.9 MAPAERO
• 10.10 PERMAGARD
• 10.11 DUNMORE
• 10.12 HEXION